Search results
Results from the WOW.Com Content Network
Estrogen dosages for menopausal hormone therapy; Route/form Estrogen Low Standard High Oral: Estradiol: 0.5–1 mg/day: 1–2 mg/day: 2–4 mg/day Estradiol valerate: 0.5–1 mg/day: 1–2 mg/day
Template:Medications and dosages used in hormone therapy for transgender men References ^ Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017).
To change this template's initial visibility, the |state= parameter may be used: {{Routes of administration, dosage forms | state = collapsed}} will show the template collapsed, i.e. hidden apart from its title bar. {{Routes of administration, dosage forms | state = expanded}} will show the template expanded, i.e. fully visible.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Donate; Pages for logged out editors learn more
[[Category:Drug templates by ATC]] to the <includeonly> section at the bottom of that page. Otherwise, add <noinclude>[[Category:Drug templates by ATC]]</noinclude> to the end of the template code, making sure it starts on the same line as the code's last character.
The Beers Criteria are intended to serve as a guide for clinicians and not as a substitute for professional judgment in prescribing decisions. The criteria may be used in conjunction with other information to guide clinicians about safe prescribing in older adults. [5] [non-primary source needed] [6] [non-primary source needed].
This is the template test cases page for the sandbox of Template:Infobox drug to update the examples. If there are many examples of a complicated template, later ones may break due to limits in MediaWiki; see the HTML comment "NewPP limit report" in the rendered page. You can also use Special:ExpandTemplates to examine the results of template uses. You can test how this page looks in the ...
6 months: 98%: 90%: 80%: 54%: 22%: 10% 12 months: 99%: 95%: 84%: 56%: 38%: 19% Notes: Prevention of breast symptoms—specifically gynecomastia and breast pain—induced by 150 mg/day bicalutamide monotherapy with tamoxifen in 282 men with prostate cancer.